Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,763
archived clinical trials in
Colitis

Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  9/27/2010
Prometheus Investigational Site #028
mi
from
Tulsa, OK
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 9/27/2010
Prometheus Investigational Site #028
mi
from
Tulsa, OK
Click here to add this to my saved trials
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  9/27/2010
Prometheus Investigational Site #030
mi
from
Philadelphia, PA
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 9/27/2010
Prometheus Investigational Site #030
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  9/27/2010
Prometheus Investigational Site #034
mi
from
Sayre, PA
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 9/27/2010
Prometheus Investigational Site #034
mi
from
Sayre, PA
Click here to add this to my saved trials
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  9/27/2010
Prometheus Investigational Site #045
mi
from
Charleston, SC
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 9/27/2010
Prometheus Investigational Site #045
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  9/27/2010
Prometheus Investigational Site #084
mi
from
Franklin, TN
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 9/27/2010
Prometheus Investigational Site #084
mi
from
Franklin, TN
Click here to add this to my saved trials
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  9/27/2010
Prometheus Investigational Site #020
mi
from
Germantown, TN
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 9/27/2010
Prometheus Investigational Site #020
mi
from
Germantown, TN
Click here to add this to my saved trials
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  9/27/2010
Prometheus Investigational Site #053
mi
from
Nashville, TN
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 9/27/2010
Prometheus Investigational Site #053
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  9/27/2010
Prometheus Investigational Site #074
mi
from
Union City, TN
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 9/27/2010
Prometheus Investigational Site #074
mi
from
Union City, TN
Click here to add this to my saved trials
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  9/27/2010
Prometheus Investigational Site 101
mi
from
Denton, TX
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 9/27/2010
Prometheus Investigational Site 101
mi
from
Denton, TX
Click here to add this to my saved trials
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  9/27/2010
Prometheus Investigational Site #071
mi
from
Plano, TX
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 9/27/2010
Prometheus Investigational Site #071
mi
from
Plano, TX
Click here to add this to my saved trials
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  9/27/2010
Prometheus Site 47
mi
from
San Antonio, TX
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 9/27/2010
Prometheus Site 47
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  9/27/2010
Prometheus Investigational Site #082
mi
from
Sugar Land, TX
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 9/27/2010
Prometheus Investigational Site #082
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  9/27/2010
Prometheus Investigational Site #012
mi
from
Ogden, UT
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 9/27/2010
Prometheus Investigational Site #012
mi
from
Ogden, UT
Click here to add this to my saved trials
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated:  9/27/2010
Prometheus Investigational Site #040
mi
from
Seattle, WA
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
Status: Enrolling
Updated: 9/27/2010
Prometheus Investigational Site #040
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated:  6/11/2011
Clinical Research Facility
mi
from
Tucson, AZ
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated: 6/11/2011
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated:  6/11/2011
Clinical Research Facility
mi
from
Anaheim, CA
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated: 6/11/2011
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated:  6/11/2011
Clinical Research Facility
mi
from
Fresno, CA
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated: 6/11/2011
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated:  6/11/2011
Clinical Research Facility
mi
from
La Jolla, CA
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated: 6/11/2011
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated:  6/11/2011
Clinical Research Facility
mi
from
Denver, CO
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated: 6/11/2011
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated:  6/11/2011
Clinical Research Facility
mi
from
Winter Park, FL
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated: 6/11/2011
Clinical Research Facility
mi
from
Winter Park, FL
Click here to add this to my saved trials
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated:  6/11/2011
Clinical Research Facility
mi
from
Atlanta, GA
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated: 6/11/2011
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated:  6/11/2011
Clinical Research Facility
mi
from
Louisville, KY
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated: 6/11/2011
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated:  6/11/2011
Clinical Research Facility
mi
from
El Paso, TX
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Status: Enrolling
Updated: 6/11/2011
Clinical Research Facility
mi
from
El Paso, TX
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Birmingham Gastroenterology Associates P.C.
mi
from
Birmingham, AL
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Birmingham Gastroenterology Associates P.C.
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Digestive Health Specialists of the Southeast
mi
from
Dothan, AL
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Digestive Health Specialists of the Southeast
mi
from
Dothan, AL
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Desert Sun Gastroenterology
mi
from
Tucson, AZ
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Desert Sun Gastroenterology
mi
from
Tucson, AZ
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Rocky Mountain Gastroenterology Associates
mi
from
Thornton, CO
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Rocky Mountain Gastroenterology Associates
mi
from
Thornton, CO
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Litchfield County Gastroenterology and Associates
mi
from
Torrington, CT
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Litchfield County Gastroenterology and Associates
mi
from
Torrington, CT
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Center for Gastrointestinal Disorders
mi
from
Hollywood, FL
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Center for Gastrointestinal Disorders
mi
from
Hollywood, FL
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Gastroenterology Group of Naples
mi
from
Naples, FL
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Gastroenterology Group of Naples
mi
from
Naples, FL
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Shafran Gastroenterology Center
mi
from
Winter Park, FL
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Shafran Gastroenterology Center
mi
from
Winter Park, FL
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Advanced Pain Care Clinic
mi
from
Evansville, IN
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Advanced Pain Care Clinic
mi
from
Evansville, IN
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Center for Digestive & Liver Diseases Inc.
mi
from
Mexico, MO
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Center for Digestive & Liver Diseases Inc.
mi
from
Mexico, MO
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
South Jersey Gastroenterology
mi
from
Marlton, NJ
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
South Jersey Gastroenterology
mi
from
Marlton, NJ
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Synergy First Medical
mi
from
Brooklyn, NY
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Synergy First Medical
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Research Associates of New York (RANY)
mi
from
New York, NY
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Research Associates of New York (RANY)
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Memphis Gastroenterology Group
mi
from
Germantown, TN
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Memphis Gastroenterology Group
mi
from
Germantown, TN
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
The First Clinic
mi
from
Nashville, TN
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
The First Clinic
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
South Texas Research Alliance
mi
from
Laredo, TX
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
South Texas Research Alliance
mi
from
Laredo, TX
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Wisconsin Center for Advanced Research
mi
from
Milwaukee, WI
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Wisconsin Center for Advanced Research
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Clinical Research of South Florida
mi
from
Boynton Beach, FL
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Clinical Research of South Florida
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Digestive Research Associates
mi
from
Newman, GA
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Digestive Research Associates
mi
from
Newman, GA
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Gastrointestinal Associates, P.A.
mi
from
Jackson, MS
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Gastrointestinal Associates, P.A.
mi
from
Jackson, MS
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Consultants for Clinical Research Inc.
mi
from
Cincinnati, OH
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Consultants for Clinical Research Inc.
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Cleveland Clinic
mi
from
Cleveland, OH
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated:  7/6/2011
Gastroenterology & Hepatology Clinic
mi
from
Abbotsford,
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis
A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
Status: Enrolling
Updated: 7/6/2011
Gastroenterology & Hepatology Clinic
mi
from
Abbotsford,
Click here to add this to my saved trials
Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants
Anti-inflammatory Treatment at the Onset of NEC in Preterm Infants- a Pilot Study
Status: Enrolling
Updated:  7/11/2011
University of Chicago Comer Children's Hospital
mi
from
Chicago, IL
Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants
Anti-inflammatory Treatment at the Onset of NEC in Preterm Infants- a Pilot Study
Status: Enrolling
Updated: 7/11/2011
University of Chicago Comer Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants
Anti-inflammatory Treatment at the Onset of NEC in Preterm Infants- a Pilot Study
Status: Enrolling
Updated:  7/11/2011
NorthShore University HealthSystem
mi
from
Evanston, IL
Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants
Anti-inflammatory Treatment at the Onset of NEC in Preterm Infants- a Pilot Study
Status: Enrolling
Updated: 7/11/2011
NorthShore University HealthSystem
mi
from
Evanston, IL
Click here to add this to my saved trials
Transition Study of Inflammatory Bowel Disease (IBD) Patients From Pediatric Gastroenterologist to Adult Gastroenterologist
Improving the Transition of Care From Pediatric GI to Adult GI for Patients With IBD: A Prospective Randomized Trial of a New Model
Status: Enrolling
Updated:  7/14/2011
The Vanderbilt Clinic
mi
from
Nashville, TN
Transition Study of Inflammatory Bowel Disease (IBD) Patients From Pediatric Gastroenterologist to Adult Gastroenterologist
Improving the Transition of Care From Pediatric GI to Adult GI for Patients With IBD: A Prospective Randomized Trial of a New Model
Status: Enrolling
Updated: 7/14/2011
The Vanderbilt Clinic
mi
from
Nashville, TN
Click here to add this to my saved trials
Transition Study of Inflammatory Bowel Disease (IBD) Patients From Pediatric Gastroenterologist to Adult Gastroenterologist
Improving the Transition of Care From Pediatric GI to Adult GI for Patients With IBD: A Prospective Randomized Trial of a New Model
Status: Enrolling
Updated:  7/14/2011
Vanderbilt Childrens Hospital/ Pediatric Gastroenterology Clinic
mi
from
Nashville, TN
Transition Study of Inflammatory Bowel Disease (IBD) Patients From Pediatric Gastroenterologist to Adult Gastroenterologist
Improving the Transition of Care From Pediatric GI to Adult GI for Patients With IBD: A Prospective Randomized Trial of a New Model
Status: Enrolling
Updated: 7/14/2011
Vanderbilt Childrens Hospital/ Pediatric Gastroenterology Clinic
mi
from
Nashville, TN
Click here to add this to my saved trials